Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Paclitaxel Poliglumex (CT-2103) vs. Paclitaxel for the Treatment of Women With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) Who Are Performance Status 2.

NCT00269828 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT00269828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00269828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Paclitaxel Poliglumex (CT-2103) vs. Paclitaxel for the Treatment of Women With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) Who Are Performance Status 2.
Lead sponsor
CTI BioPharma
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2005
Completion date
December 31, 2006
Enrollment
600
Sites
143

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc